Dianthus Therapeutics, Inc. /DE/ Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax of $2.16 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $2.16M.
- 2026-03-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $680.00K.
- 2025-12-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $22.00K.
- 2025-09-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $185.00K.
| Period end | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax as first filed |
|---|---|---|
| 2026-06-30 | $2.16M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $680.00K 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $22.00K 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $185.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $62.00K 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $40.00K 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $139.00K 10-K · filed 2026-03-09 | |
| 2024-09-30 | $6.00K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $37.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $28.00K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $1.00K 10-K · filed 2025-03-11 | |
| 2023-09-30 | $2.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $5.00K 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $17.00K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $164.00K 10-K · filed 2024-03-21 | $183.00K 10-K · filed 2023-03-23 |
| 2022-09-30 | $462.00K 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $602.00K 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $469.00K 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $30.00K 10-K · filed 2023-03-23 | |
| 2020-12-31 | $23.00K 10-K · filed 2022-03-08 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $21.00K 10-K · filed 2021-03-03 | |
| 2019-03-31 | $1.00K 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $14.00K 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |